Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292408 | 0.84 | PKM (0.33) | PKMTSHR | |
| SCHEMBL294994 | 0.83 | PKM (0.33) | PKMTSHR | |
| SCHEMBL293784 | 0.82 | PKM (0.34) | PKMTSHR | |
| SCHEMBL9834913 | 0.82 | PKM (0.34) | PKMTSHR | |
| SCHEMBL29794229 | 0.82 | TSHR (0.34) | PKMTSHRKCNH2 | |
| SCHEMBL25718526 | 0.81 | TSHR (0.38) | PKMTSHRKCNH2 | |
| SCHEMBL293833 | 0.78 | PKM (0.36) | PKMTSHR | |
| SCHEMBL295321 | 0.74 | PKM (0.38) | PKMTSHR | |
| SCHEMBL9768971 | 0.74 | PKM (0.38) | PKMTSHR | |
| SCHEMBL9724429 | 0.74 | PKM (0.38) | PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104860915-B | A kind of preparation method of 4H-4-aryl benzopyrans compounds | 昆明理工大学 | 2016-11-23 | — | — | CN | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102702182-A | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102558140-A | Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-101258147-B | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD | 2012-03-21 | — | — | CN | disclosed |
| US-7968595-B2 | R-stereoisomer of 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H-chromene; treating solid tumors and ocular neovascularization; combination therapy; prodrugs made by reacting with protected amino acid | CYTOVIA, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| CN-101657196-A | Substituted 4-aryl-chromenes as activators of caspases and inducers of apoptosis and antiangiogenic agents and use thereof | CYTOVIA INC US | 2010-02-24 | — | — | CN | disclosed |
| CN-101657196-A | Substituted 4-aryl-chromenes as activators of caspases and inducers of apoptosis and antiangiogenic agents and use thereof | CYTOVIA INC US | 2010-02-24 | — | — | CN | disclosed |
| CN-101258147-A | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-20080085328-A1 | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof | DISCOVER GROWTH FUND, LLC (VI) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085328-A1 | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof | CASP1, CASP2, CASP3 | PTPN1 2830/4885CNR1 850/4885CYP1A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.